Robert Kamen, Ph.D., Joins ShangBay Capital as a Senior Advisor
PALO ALTO, Calif.--(BUSINESS WIRE)--ShangBay Capital, a venture capital firm focused on investing in early-stage healthcare companies, today announced that Robert Kamen, Ph.D., has joined its advisory team as a Senior Advisor. The venture capital firm is one of the most prolific investors in medtech. Dr. Kamen will provide tremendous value in the biotech and biopharma investment fields for potential new companies.
ShangBay Capital’s team has a proven track record of identifying, financing, and building various healthcare companies over the last several years. The team brings deep operational experience from more than 100 years of combined industry experience to help entrepreneurs build lasting companies.
“Bob will bring significant value from his more than 35 years of experience of launching and operating successful biotech and pharmaceutical companies,” said William Dai, Founding Managing Partner. “His in-depth experience will help ShangBay continue to build a great portfolio of disruptive biotechnologies to improve patient outcome.”
Dr. Kamen is also a venture partner at Third Rock Ventures. Prior to that, he served as an executive-in-residence at Oxford Bioscience Partners. Dr. Kamen’s career began as Senior VP Scientific Affairs at Genetics Institute, Inc., a pioneering biopharmaceutical firm that was acquired by Wyeth. He previously served as president of Abbott Bioresearch Center, where he oversaw the discovery and production of Humira, the first fully human antibody to achieve marketing approval in the U.S. and Europe and was a member of the Abbott Pharmaceuticals Executive Management Committee. He also was the president of the BASF Bioresearch Corp. until it was acquired by Abbott Laboratories in 2001. Dr. Kamen is a co-founder of BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases, that was acquired by Cephalon. Dr. Kamen serves as a director of Jounce Therapeutics, Harbour Biomed, and EpimAb Biotherapeutics. He previously served as a director at Neon Therapeutics, Harbour Antibodies, Lycera, Opsonic Therapeutics, and Anchor Therapeutics and was a member of the GlaxoSmithKline Biopharma Investment Board. Dr. Kamen received his undergraduate degree in biophysics from Amherst College (summa cum laude) and his Ph.D. in biochemistry and molecular biology from Harvard University.
About ShangBay Capital
Founded in 2015, ShangBay Capital is a Silicon Valley-based venture capital company that brings investors access to best-in-class investments in U.S. medical device technologies, biotechnology, biopharmaceutical, and digital health sectors through early-stage venture equity participation.